dc.contributor.author | Meraldi, V | |
dc.contributor.author | Audran, R | |
dc.contributor.author | Romero, JF | |
dc.contributor.author | Brossard, V | |
dc.contributor.author | Bauer, J | |
dc.contributor.author | Lopez, JA | |
dc.contributor.author | Corradin, G | |
dc.date.accessioned | 2017-05-03T16:58:39Z | |
dc.date.available | 2017-05-03T16:58:39Z | |
dc.date.issued | 2003 | |
dc.date.modified | 2009-12-21T06:45:35Z | |
dc.identifier.issn | 0264-410X | |
dc.identifier.doi | 10.1016/S0264-410X(03)00093-8 | |
dc.identifier.uri | http://hdl.handle.net/10072/27866 | |
dc.description.abstract | The goal of this project was the evaluation of a novel immunomodulatory adjuvant for human use, OM-174, which is a soluble adjuvant derived from Escherichia coli lipid A. For this study, we used a synthetic peptide, known for its safety and reproducibility and the murine model of BALB/c mice. The long peptide (PbCS 242-310) used corresponds to the C-terminal region of the circumsporozoite protein (CSP) that is the major protein on the surface of Plasmodium sporozoites. Subcutaneous injections of PbCS 242-310 in combination with soluble adjuvant OM-174 induced long lasting peptide-specific antibody titres comparable to those obtained by immunization with incomplete Freund's adjuvant (IFA). The ex vivo evaluation of the CD8+ T cell response by IFN-? ELISPOT assay revealed that the injection of polypeptide with OM-174 adjuvant induced, compared to IFA, a similar and an eight-fold increased frequency of peptide-specific lymphocytes in the draining lymph-nodes and in the spleen, respectively. The CD8+ T-cells are specific for the sequence PbCS 245-253, a well-known H-2Kd-restricted CTL epitope, and are cytotoxic as shown in a chromium release assay. Immunization of BALB/c mice with this polypeptide in combination with adjuvant OM-174 conferred a protection after challenge with live Plasmodium berghei sporozoites. The strong antibody and CTL responses observed to a synthetic peptide in mice, the safety profile of the adjuvant and its extensive physico-chemical characterization suggest that OM-174 has a potential use in vaccine formulations for humans. | |
dc.description.peerreviewed | Yes | |
dc.description.publicationstatus | Yes | |
dc.language | English | |
dc.language.iso | eng | |
dc.publisher | Elsevier | |
dc.publisher.place | United States of America | |
dc.relation.ispartofpagefrom | 2485 | |
dc.relation.ispartofpageto | 2491 | |
dc.relation.ispartofissue | 19-20 | |
dc.relation.ispartofjournal | Vaccine | |
dc.relation.ispartofvolume | 21 | |
dc.subject.fieldofresearch | Biological sciences | |
dc.subject.fieldofresearch | Agricultural, veterinary and food sciences | |
dc.subject.fieldofresearch | Biomedical and clinical sciences | |
dc.subject.fieldofresearch | Immunology not elsewhere classified | |
dc.subject.fieldofresearchcode | 31 | |
dc.subject.fieldofresearchcode | 30 | |
dc.subject.fieldofresearchcode | 32 | |
dc.subject.fieldofresearchcode | 320499 | |
dc.title | OM-174, a new adjuvant with a potential for human use, induces a protective response when administered with the synthetic C-terminal fragment 242-310 from the circumsporozoite protein of Plasmodium berghei | |
dc.type | Journal article | |
dc.type.description | C1 - Articles | |
dc.type.code | C - Journal Articles | |
gro.date.issued | 2003 | |
gro.hasfulltext | No Full Text | |
gro.griffith.author | Lopez Ramirez, Alejandro | |